Skip to content

Blue Light Therapy for Liver Surgery

Blue Light Therapy for Liver Surgery

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02915081
Enrollment
6
Registered
2016-09-26
Start date
2017-01-01
Completion date
2018-12-31
Last updated
2019-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Liver Injury, Inflammation

Brief summary

The investigators hypothesize that subjects undergoing liver resection and who are exposed preoperatively to high illuminance blue spectrum light will exhibit reduced organ injury, specifically liver dysfunction, than subjects exposed to standard ambient white fluorescent light.

Interventions

Illumination: High illumination lighting will be instituted with a Day\*Light Classic Light (Uplift Technologies, Dartmouth, NS) Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches. Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
University of Pittsburgh Medical Center
CollaboratorOTHER
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* age greater than 17 years * undergoing right or left hepatic lobectomy

Exclusion criteria

* presence of acute traumatic brain injury * blindness * immunosuppression or immunocompromised condition

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline creatinine concentration at 24 hours after surgerypreoperatively and 24 hours after surgerya serum marker of acute kidney injury
Change from baseline alanine aminotransferase (ALT) concentration at 24 hours after surgerypreoperatively and 24 hours after surgerya serum marker of acute liver injury

Secondary

MeasureTime frameDescription
ICU length of stayfor the duration of postoperative inpatient hospital stay up to 28 days
Change in serum cytokine concentrations at 24 hours after surgery24 hours after surgeryserum will be analyzed for cytokines and inflammatory mediators
Change in serum cytokine concentrations at 1 hour after surgery1 hours after surgeryserum will be analyzed for cytokines and inflammatory mediators
renal replacement therapyfor the duration of postoperative inpatient hospital stay up to 28 days
Ventilator-free daysfor the duration of postoperative inpatient hospital stay up to 28 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026